Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.85 |
| ▸ | RAB9A | P51151 | 9/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | ATM | Q13315 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333970 | 0.82 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8116943 | 0.81 | TSHR (0.61) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6211660 | 0.81 | ALDH1A1 (0.61) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21935282 | 0.81 | RAB9A (0.84) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10305252 | 0.80 | ROCK2 (0.67) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30329933 | 0.80 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4456132 | 0.80 | MAPT (0.84) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL592825 | 0.78 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5060744 | 0.78 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL592296 | 0.77 | ALDH1A1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| EP-2344485-B1 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-22 | — | — | EP | disclosed |
| EP-2915813-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2146987-B1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-02 | — | — | EP | disclosed |
| EP-2144910-B1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2146987-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-27 | — | — | EP | disclosed |
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009104147-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-2001478-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008126024-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007107965-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | NPC1 1979/4885RAB9A 2830/4885SMN1; SMN2 4195/4885 |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | CBR3, RXFP4, ODC1 | NPC1 3633/4885RAB9A 1339/4885SMN1; SMN2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.